fingolimod hydrochloride has been researched along with Neurodegenerative Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 6 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busra Azizoglu, Z; Canatan, H; Eken, A; Zehra Okus, F | 1 |
| Alasmari, AF; Alharbi, M; Alshammari, A; Assiri, MA; Kalfin, R; Kapoor, T; Kumar, N; Mehan, S; Narula, AS; Sharma, N; Suri, M | 1 |
| Achiron, A; Angelucci, F; Halusková, S; Hartung, HP; Mareš, J; Pavelek, Z; Štourač, P; Tichá, V; Vališ, M | 1 |
| Baradaran, B; Barpour, N; Dabbaghi, R; Hosseinpourfeizi, M; Rahmani, S; Rajabi, A; Safaralizadeh, R | 1 |
| Chen, CP; Chew, WS; Chua, XY; Herr, DR; Ho, LTY; Lai, MKP; Lam, BWS; Ong, WY; Xiang, P | 1 |
| Boraldi, F; Claros, S; Fernández, O; Garcia-Fernandez, M; Gil, A; Lara, E; Martín-Montañez, E; Pavia, J; Romero-Zerbo, SY; Valverde, N | 1 |
| Cooper, JD; Nelvagal, HR | 1 |
| Amico, E; Castrataro, R; Di Pardo, A; Favellato, M; Fucile, S; Maglione, V; Squitieri, F | 1 |
2 review(s) available for fingolimod hydrochloride and Neurodegenerative Diseases
| Article | Year |
|---|---|
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neurodegenerative Diseases; Recurrence; Risk Assessment | 2023 |
Preclinical and Clinical Evidence for the Involvement of Sphingosine 1-Phosphate Signaling in the Pathophysiology of Vascular Cognitive Impairment.
Topics: Aldehyde-Lyases; Alzheimer Disease; Animals; Cerebrovascular Disorders; Clinical Trials as Topic; Dementia, Vascular; Drug Delivery Systems; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Humans; Infarction, Middle Cerebral Artery; Inflammation; Ischemic Stroke; Lysophospholipids; Mice; Mice, Knockout; Neurodegenerative Diseases; Phosphotransferases (Alcohol Group Acceptor); Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors | 2021 |
6 other study(ies) available for fingolimod hydrochloride and Neurodegenerative Diseases
| Article | Year |
|---|---|
S1P analogues SEW2871, BAF312 and FTY720 affect human Th17 and Treg generation ex vivo.
Topics: Animals; Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interleukin-23; Lysophospholipids; Mice; Neurodegenerative Diseases; Oxadiazoles; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes, Regulatory; Th17 Cells; Thiophenes | 2022 |
Forskolin, an Adenylcyclase/cAMP/CREB Signaling Activator Restoring Myelin-Associated Oligodendrocyte Destruction in Experimental Ethidium Bromide Model of Multiple Sclerosis.
Topics: Adenylyl Cyclases; Animals; Colforsin; Cytokines; Demyelinating Diseases; Donepezil; Ethidium; Fingolimod Hydrochloride; Gliotoxin; Memantine; Multiple Sclerosis; Myelin Basic Protein; Myelin Sheath; Nerve Growth Factors; Neurodegenerative Diseases; Oligodendroglia; Rats; Rats, Wistar; Simvastatin | 2022 |
The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients.
Topics: Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon-gamma; Leukocytes, Mononuclear; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neurodegenerative Diseases | 2023 |
Neuronal Metabolism and Neuroprotection: Neuroprotective Effect of Fingolimod on Menadione-Induced Mitochondrial Damage.
Topics: Animals; Antioxidants; Cell Line; Fingolimod Hydrochloride; Glycolysis; Mice; Mitochondria; Neurodegenerative Diseases; Neurons; Neuroprotection; Neuroprotective Agents; Oxidative Stress; Sphingosine-1-Phosphate Receptors; Vitamin K 3 | 2020 |
Progress toward Fulfilling the Potential of Immunomodulation in Childhood Neurodegeneration?
Topics: Animals; Crotonates; Disease Models, Animal; Fingolimod Hydrochloride; Hydroxybutyrates; Immunomodulation; Mice; Neurodegenerative Diseases; Neuronal Ceroid-Lipofuscinoses; Nitriles; Toluidines | 2017 |
FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.
Topics: Animals; Brain; Cell Line; Disease Models, Animal; Fingolimod Hydrochloride; Huntington Disease; Immunoblotting; Immunohistochemistry; Male; Mice; Mice, Transgenic; Neurodegenerative Diseases; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Real-Time Polymerase Chain Reaction; Sphingosine | 2014 |